Catalyst Pharmaceuticals, Inc. - Common Stock (CPRX)
31.17
+0.00 (0.00%)
NASDAQ · Last Trade: May 8th, 6:21 AM EDT
Detailed Quote
Previous Close
31.17
Open
-
Bid
31.10
Ask
31.20
Day's Range
N/A - N/A
52 Week Range
19.05 - 32.56
Volume
303
Market Cap
3.20B
PE Ratio (TTM)
18.44
EPS (TTM)
1.7
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,502,780
Chart
About Catalyst Pharmaceuticals, Inc. - Common Stock (CPRX)
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for individuals with rare neurological and neuromuscular diseases. The company’s primary emphasis is on conditions like myasthenia gravis, creating targeted treatments that aim to improve patient outcomes and quality of life. Catalyst Pharmaceuticals is committed to advancing its drug pipeline through research, development, and collaboration, striving to address unmet medical needs in the rare disease landscape. With a patient-centered approach, the company aims to transform the treatment paradigm in its specialized therapeutic areas. Read More
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) to Angelini Pharma S.p.A. for $31.50 per share in cash.
Catalyst Pharmaceuticals (CPRX) combines strong growth, high profitability, and a debt-free balance sheet with a positive technical trend, signaling a potential breakout opportunity.
Catalyst Pharmaceuticals (CPRX) exemplifies affordable growth with strong earnings, a debt-free balance sheet, and a valuation below industry averages.
CORAL GABLES, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company will showcase real‑world findings in Duchenne muscular dystrophy (DMD) through multiple poster presentations at the 2026 MDA Clinical & Scientific Conference in Orlando, Florida. Catalyst will also sponsor a vamorolone-focused MDA Industry Forum with Santhera Pharmaceuticals.
CORAL GABLES, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026, being held in Miami, Florida.
Catalyst Pharmaceuticals (CPRX) exemplifies the GARP strategy with strong growth, high profitability, and a reasonable valuation in the biotech sector.
